Sign up to SCR Digest, our FREE weekly newsletter, and receive our Notes emailed directly to you.
Email Address *
First Name
Mailing Lists *

CKPT: CK-101 Data Announced



Checkpoint Therapeutics (NASDAQ:CKPT) announced today that it will present results from the CK-101 Phase I/II program at the World Conference on Lung Cancer on Monday, September 24 in Toronto, Canada. CK-101 is the company’s lead candidate -- a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) indicated for non-small cell lung cancer (NSCLC). Preliminary safety and efficacy data is now available and has been selected for presentation at a late-breaking oral session at the conference. This NSCLC drug is expected to address many of the shortcomings in previous generation drugs. This includes the development of resistance and emergence of adverse side effects for other EGFR TKIs.

The title of the upcoming presentation is “CK-101 (RX518), a Third Generation Mutant-Selective Inhibitor of EGFR in NSCLC: Results of an Ongoing Phase I/II Trial.” The associated abstract will be available September 5th on the conference website. Dr. Melissa Johnson who is the Associate Director, Lung Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology will present the data at the novel therapies in lung cancer session.

Checkpoint began enrolling for this study (NCT02926768) in September 2016 and began Phase II in late 2017. Results are expected to show a more favorable side effect profile as compared to market leader Tagrisso. Tagrisso suffered from incidence of interstitial lung disease (ILD) in both mono and combination therapy in contrast to preclinical and Phase I data for CK-101 which has not shown any evidence of ILD. With fewer side effects and similar efficacy, it is likely CK-101 could take material market share in this $5 billion space.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.
User ID:
Remember my ID: